Abiraterone
The serum concentration of Irbesartan can be increased when it is combined with Abiraterone.
Acebutolol
Irbesartan may increase the hypotensive activities of Acebutolol.
Aceclofenac
The metabolism of Aceclofenac can be decreased when combined with Irbesartan.
Advertisement
Acemetacin
The therapeutic efficacy of Irbesartan can be decreased when used in combination with Acemetacin.
Acenocoumarol
The metabolism of Acenocoumarol can be decreased when combined with Irbesartan.
Acetaminophen
The metabolism of Acetaminophen can be decreased when combined with Irbesartan.
Advertisement
Acetyl salicylate
The metabolism of Acetylsalicylic acid can be decreased when combined with Irbesartan.
Acetyl Sulfisoxazole
The metabolism of Irbesartan can be decreased when combined with Acetyl sulfisoxazole.
Adapalene
The risk or severity of adverse effects can be increased when Irbesartan is combined with Adapalene.
Advertisement
Aldesleukin
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Irbesartan.
Alfuzosin
Alfuzosin may increase the hypotensive activities of Irbesartan.
Aliskiren
Aliskiren may increase the hyperkalemic activities of Irbesartan.
Alminoprofen
The risk or severity of adverse effects can be increased when Irbesartan is combined with Alminoprofen.
Almotriptan
The metabolism of Almotriptan can be decreased when combined with Irbesartan.
Alosetron
The metabolism of Alosetron can be decreased when combined with Irbesartan.
Alprazolam
The metabolism of Alprazolam can be decreased when combined with Irbesartan.
Alprenolol
Alprenolol may increase the hypotensive activities of Irbesartan.
Ambrisentan
Irbesartan may increase the hypotensive activities of Ambrisentan.
Amifostine
Irbesartan may increase the hypotensive activities of Amifostine.
Amifostine Anhydrous
Irbesartan may increase the hypotensive activities of Amifostine.
Amiloride
Irbesartan may increase the hyperkalemic activities of Amiloride.
Aminopyrine
The metabolism of Aminophenazone can be decreased when combined with Irbesartan.
Amiodarone
The metabolism of Irbesartan can be decreased when combined with Amiodarone.
Amitriptyline
The metabolism of Amitriptyline can be decreased when combined with Irbesartan.
Amlodipine
Amlodipine may increase the hypotensive activities of Irbesartan.
Amobarbital
Amobarbital may increase the hypotensive activities of Irbesartan.
Amodiaquine
The serum concentration of Amodiaquine can be increased when it is combined with Irbesartan.
Amphetamine
Amphetamine may increase the hypotensive activities of Irbesartan.
Amphotericin B
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Irbesartan.
amphotericin B liposomal
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Irbesartan.
Amprenavir
The metabolism of Amprenavir can be decreased when combined with Irbesartan.
Amyl Nitrite
The risk or severity of adverse effects can be increased when Irbesartan is combined with Amyl Nitrite.
Antipyrine
The metabolism of Antipyrine can be decreased when combined with Irbesartan.
Apalutamide
The serum concentration of Irbesartan can be decreased when it is combined with Apalutamide.
Apazone
The risk or severity of adverse effects can be increased when Irbesartan is combined with Azapropazone.
Apixaban
The metabolism of Apixaban can be decreased when combined with Irbesartan.
Apomorphine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Irbesartan.
Apraclonidine
The risk or severity of adverse effects can be increased when Apraclonidine is combined with Irbesartan.
Apremilast
The risk or severity of adverse effects can be increased when Irbesartan is combined with Apremilast.
Aprepitant
The metabolism of Irbesartan can be increased when combined with Aprepitant.
Arachidonic Acid
The metabolism of Arachidonic Acid can be decreased when combined with Irbesartan.
Ardeparin
Ardeparin may increase the hyperkalemic activities of Irbesartan.
Arformoterol
The metabolism of Arformoterol can be decreased when combined with Irbesartan.
Aripiprazole
Aripiprazole may increase the hypotensive activities of Irbesartan.
Arsenic Trioxide
The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Irbesartan.
Artemether
The metabolism of Artemether can be decreased when combined with Irbesartan.
Aspirin
The metabolism of Acetylsalicylic acid can be decreased when combined with Irbesartan.
Asunaprevir
The serum concentration of Asunaprevir can be increased when it is combined with Irbesartan.
Atazanavir
The metabolism of Atazanavir can be decreased when combined with Irbesartan.
Atenolol
Atenolol may increase the hypotensive activities of Irbesartan.
Atorvastatin
The risk or severity of adverse effects can be increased when Irbesartan is combined with Atorvastatin.
Avanafil
Avanafil may increase the antihypertensive activities of Irbesartan.
Avatrombopag
The metabolism of Avatrombopag can be decreased when combined with Irbesartan.
Azelastine
The metabolism of Azelastine can be decreased when combined with Irbesartan.
Azilsartan
The risk or severity of adverse effects can be increased when Irbesartan is combined with Azilsartan medoxomil.
Azilsartan kamedoxomil
The risk or severity of adverse effects can be increased when Irbesartan is combined with Azilsartan medoxomil.
Azilsartan Medoxomil
The risk or severity of adverse effects can be increased when Irbesartan is combined with Azilsartan medoxomil.
Balsalazide
The risk or severity of adverse effects can be increased when Irbesartan is combined with Balsalazide.
Barbexaclone
Barbexaclone may increase the hypotensive activities of Irbesartan.
Barbital
Barbital may increase the hypotensive activities of Irbesartan.
Bemiparin
Bemiparin may increase the hyperkalemic activities of Irbesartan.
Benazepril
The risk or severity of adverse effects can be increased when Irbesartan is combined with Benazepril.
Bendroflumethiazide
Bendroflumethiazide may increase the hypotensive activities of Irbesartan.
Benzydamine
The risk or severity of adverse effects can be increased when Irbesartan is combined with Benzydamine.
Benzyl Alcohol
The metabolism of Benzyl alcohol can be decreased when combined with Irbesartan.
Bepridil
Irbesartan may increase the hypotensive activities of Bepridil.
Betaxolol
Betaxolol may increase the hypotensive activities of Irbesartan.
Bethanidine
Bethanidine may increase the hypotensive activities of Irbesartan.
Bexarotene
The metabolism of Bexarotene can be decreased when combined with Irbesartan.
Bimatoprost
Bimatoprost may increase the hypotensive activities of Irbesartan.
Bioallethrin
The metabolism of Bioallethrin can be decreased when combined with Irbesartan.
Bisoprolol
Bisoprolol may increase the hypotensive activities of Irbesartan.
Bortezomib
The metabolism of Bortezomib can be decreased when combined with Irbesartan.
Bosentan
The serum concentration of Bosentan can be increased when it is combined with Irbesartan.
Bosentan Anhydrous
The serum concentration of Bosentan can be increased when it is combined with Irbesartan.
Bosutinib
The serum concentration of Bosutinib can be increased when it is combined with Irbesartan.
Bosutinib monohydrate
The serum concentration of Bosutinib can be increased when it is combined with Irbesartan.
Bretylium
Irbesartan may increase the hypotensive activities of Bretylium.
Brigatinib
The metabolism of Brigatinib can be decreased when combined with Irbesartan.
Brimonidine
Brimonidine may increase the antihypertensive activities of Irbesartan.
Brivaracetam
The metabolism of Brivaracetam can be decreased when combined with Irbesartan.
Bromfenac
The risk or severity of adverse effects can be increased when Irbesartan is combined with Bromfenac.
Bromocriptine
The risk or severity of adverse effects can be increased when Bromocriptine is combined with Irbesartan.
Brompheniramine
The metabolism of Brompheniramine can be decreased when combined with Irbesartan.
Bufexamac
The risk or severity of adverse effects can be increased when Irbesartan is combined with Bufexamac.
Bumetanide
The risk or severity of adverse effects can be increased when Bumetanide is combined with Irbesartan.
Bupivacaine
The risk or severity of adverse effects can be increased when Bupivacaine is combined with Irbesartan.
Bupranolol
Irbesartan may increase the hypotensive activities of Bupranolol.
Buprenorphine
The metabolism of Buprenorphine can be decreased when combined with Irbesartan.
Bupropion
The metabolism of Bupropion can be decreased when combined with Irbesartan.
Cabazitaxel
The metabolism of Cabazitaxel can be decreased when combined with Irbesartan.
Cabergoline
The risk or severity of adverse effects can be increased when Cabergoline is combined with Irbesartan.
Cabozantinib
The metabolism of Cabozantinib can be decreased when combined with Irbesartan.
Cafedrine
Irbesartan may increase the hypotensive activities of Cafedrine.
Caffeine
The metabolism of Caffeine can be decreased when combined with Irbesartan.
Canagliflozin
Canagliflozin may increase the hyperkalemic activities of Irbesartan.
Canagliflozin Anhydrous
Canagliflozin may increase the hyperkalemic activities of Irbesartan.
Candesartan
The metabolism of Candesartan can be decreased when combined with Irbesartan.
Candesartan Cilexetil
The metabolism of Candesartan cilexetil can be decreased when combined with Irbesartan.
Cannabidiol
The metabolism of Cannabidiol can be decreased when combined with Irbesartan.
Cannavis sativa susp. indica top extract
The metabolism of Medical Cannabis can be decreased when combined with Irbesartan.
Capecitabine
The metabolism of Irbesartan can be decreased when combined with Capecitabine.
Captopril
The risk or severity of adverse effects can be increased when Irbesartan is combined with Captopril.
Carbamazepine
The metabolism of Irbesartan can be increased when combined with Carbamazepine.
Carbinoxamine
The metabolism of Carbinoxamine can be decreased when combined with Irbesartan.
Carprofen
The risk or severity of adverse effects can be increased when Irbesartan is combined with Carprofen.
Carteolol
Carteolol may increase the hypotensive activities of Irbesartan.
Carvedilol
The serum concentration of Carvedilol can be increased when it is combined with Irbesartan.
Celecoxib
The metabolism of Celecoxib can be decreased when combined with Irbesartan.
Celiprolol
Irbesartan may increase the hypotensive activities of Celiprolol.
Ceritinib
The serum concentration of Irbesartan can be increased when it is combined with Ceritinib.
Cerivastatin
The serum concentration of Cerivastatin can be increased when it is combined with Irbesartan.
Certoparin
Certoparin may increase the hyperkalemic activities of Irbesartan.
Chloroquine
The metabolism of Chloroquine can be decreased when combined with Irbesartan.
Chlorothiazide
Chlorothiazide may increase the hypotensive activities of Irbesartan.
Chlorpromazine
The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Irbesartan.
Chlorpropamide
The metabolism of Chlorpropamide can be decreased when combined with Irbesartan.
Chlorthalidone
Chlorthalidone may increase the hypotensive activities of Irbesartan.
Cholecalciferol
The metabolism of Irbesartan can be decreased when combined with Cholecalciferol.
Choline Magnesium Trisalicyclate
The risk or severity of adverse effects can be increased when Irbesartan is combined with Choline magnesium trisalicylate.
Cicletanine
Irbesartan may increase the hypotensive activities of Cicletanine.
Cilazapril
The risk or severity of adverse effects can be increased when Irbesartan is combined with Cilazapril.
Cinnarizine
The metabolism of Cinnarizine can be decreased when combined with Irbesartan.
Ciprofloxacin
Irbesartan may increase the arrhythmogenic activities of Ciprofloxacin.
Cisapride
The metabolism of Cisapride can be decreased when combined with Irbesartan.
Clevidipine
The risk or severity of adverse effects can be increased when Irbesartan is combined with Clevidipine.
Clevidipine butyrate
The risk or severity of adverse effects can be increased when Irbesartan is combined with Clevidipine.
Clofarabine
The risk or severity of adverse effects can be increased when Clofarabine is combined with Irbesartan.
Clofezone
The metabolism of Irbesartan can be decreased when combined with Rabeprazole.
Clomipramine
The risk or severity of adverse effects can be increased when Clomipramine is combined with Irbesartan.
Clonidine
Clonidine may increase the hypotensive activities of Irbesartan.
Clonixin
The risk or severity of adverse effects can be increased when Irbesartan is combined with Clonixin.
Clopidogrel
The metabolism of Clopidogrel can be decreased when combined with Irbesartan.
Clotrimazole
The metabolism of Irbesartan can be decreased when combined with Clotrimazole.
Clozapine
The metabolism of Clozapine can be decreased when combined with Irbesartan.
Conivaptan
The risk or severity of adverse effects can be increased when Conivaptan is combined with Irbesartan.
Crisaborole
The metabolism of Irbesartan can be decreased when combined with Crisaborole.
Cryptenamine
Cryptenamine may increase the hypotensive activities of Irbesartan.
Curcumin
The metabolism of Irbesartan can be decreased when combined with Curcumin.
Cyclopenthiazide
Irbesartan may increase the hypotensive activities of Cyclopenthiazide.
Cyclophosphamide
The metabolism of Cyclophosphamide can be decreased when combined with Irbesartan.
Cyclophosphamide Anhydrous
The metabolism of Cyclophosphamide can be decreased when combined with Irbesartan.
Cyclosporine
Irbesartan may increase the hyperkalemic activities of Cyclosporine.
Cyclothiazide
Cyclothiazide may increase the hypotensive activities of Irbesartan.
Dabrafenib
The serum concentration of Irbesartan can be decreased when it is combined with Dabrafenib.
Dalteparin
Dalteparin may increase the hyperkalemic activities of Irbesartan.
Dapagliflozin
The metabolism of Dapagliflozin can be decreased when combined with Irbesartan.
Dapsone
The metabolism of Dapsone can be decreased when combined with Irbesartan.
Dasabuvir
The metabolism of Dasabuvir can be decreased when combined with Irbesartan.
Debrisoquin
Debrisoquin may increase the hypotensive activities of Irbesartan.
Deferasirox
The serum concentration of Irbesartan can be increased when it is combined with Deferasirox.
Delavirdine
The metabolism of Irbesartan can be decreased when combined with Delavirdine.
Deserpidine
Irbesartan may increase the hypotensive activities of Deserpidine.
Desflurane
The risk or severity of adverse effects can be increased when Desflurane is combined with Irbesartan.
Dexmedetomidine
The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Irbesartan.
Dextromethorphan
The metabolism of Dextromethorphan can be decreased when combined with Irbesartan.
Diazepam
The metabolism of Diazepam can be decreased when combined with Irbesartan.
Diazoxide
Diazoxide may increase the hypotensive activities of Irbesartan.
Dichlorphenamide
The risk or severity of adverse effects can be increased when Irbesartan is combined with Diclofenamide.
Diclofenac
The metabolism of Diclofenac can be decreased when combined with Irbesartan.
Dicumarol
The metabolism of Dicoumarol can be decreased when combined with Irbesartan.
Diflunisal
The risk or severity of adverse effects can be increased when Irbesartan is combined with Diflunisal.
Dihydralazine
Dihydralazine may increase the hypotensive activities of Irbesartan.
Dihydroergocornine
The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Irbesartan.
Dihydroergocristine
The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Irbesartan.
Dihydroergotamine
The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Irbesartan.
Diltiazem
The metabolism of Diltiazem can be decreased when combined with Irbesartan.
Dinutuximab
The risk or severity of adverse effects can be increased when Irbesartan is combined with Dinutuximab.
Diphenhydramine
The metabolism of Diphenhydramine can be decreased when combined with Irbesartan.
Dipyridamole
The risk or severity of adverse effects can be increased when Dipyridamole is combined with Irbesartan.
Dipyrone
The risk or severity of adverse effects can be increased when Irbesartan is combined with Metamizole.
Doconexent
The metabolism of Doconexent can be decreased when combined with Irbesartan.
Dolasetron
The metabolism of Dolasetron can be decreased when combined with Irbesartan.
Domperidone
The metabolism of Domperidone can be decreased when combined with Irbesartan.
Donepezil
The metabolism of Donepezil can be decreased when combined with Irbesartan.
Dopamine
The metabolism of Dopamine can be decreased when combined with Irbesartan.
Dorzolamide
The metabolism of Dorzolamide can be decreased when combined with Irbesartan.
Dothiepin
The metabolism of Irbesartan can be decreased when combined with Dosulepin.
Doxazosin
Doxazosin may increase the hypotensive activities of Irbesartan.
Doxepin
The metabolism of Doxepin can be decreased when combined with Irbesartan.
Drospirenone
Irbesartan may increase the hyperkalemic activities of Drospirenone.
Droxicam
The risk or severity of adverse effects can be increased when Irbesartan is combined with Droxicam.
Duloxetine
Irbesartan may increase the orthostatic hypotensive activities of Duloxetine.
Efavirenz
The metabolism of Irbesartan can be decreased when combined with Efavirenz.
Eletriptan
The metabolism of Eletriptan can be decreased when combined with Irbesartan.
Eltrombopag
The metabolism of Eltrombopag can be decreased when combined with Irbesartan.
Empagliflozin
The risk or severity of adverse effects can be increased when Irbesartan is combined with Empagliflozin.
Enalapril
The risk or severity of adverse effects can be increased when Irbesartan is combined with Enalapril.
Enalaprilat
The risk or severity of adverse effects can be increased when Irbesartan is combined with Enalaprilat.
Enalaprilat Anhydrous
The risk or severity of adverse effects can be increased when Irbesartan is combined with Enalaprilat.
Enasidenib
The metabolism of Enasidenib can be decreased when combined with Irbesartan.
Enoxaparin
Enoxaparin may increase the hyperkalemic activities of Irbesartan.
Enoxaparin sodium
Enoxaparin may increase the hyperkalemic activities of Irbesartan.
Enzalutamide
The metabolism of Enzalutamide can be decreased when combined with Irbesartan.
Eplerenone
Eplerenone may increase the hyperkalemic activities of Irbesartan.
Epoprostenol
The metabolism of Epoprostenol can be decreased when combined with Irbesartan.
Eprosartan
Eprosartan may increase the hypotensive activities of Irbesartan.
Ergonovine
The risk or severity of adverse effects can be increased when Ergonovine is combined with Irbesartan.
Ergotamine
The risk or severity of adverse effects can be increased when Ergotamine is combined with Irbesartan.
Erlotinib
The metabolism of Erlotinib can be decreased when combined with Irbesartan.
Esmolol
The risk or severity of adverse effects can be increased when Esmolol is combined with Irbesartan.
Estradiol
The metabolism of Estradiol can be decreased when combined with Irbesartan.
Estradiol 3-Benzoate
The metabolism of Estradiol benzoate can be decreased when combined with Irbesartan.
Estradiol acetate
The metabolism of Estradiol acetate can be decreased when combined with Irbesartan.
Estradiol Cypionate
The metabolism of Estradiol cypionate can be decreased when combined with Irbesartan.
Estradiol Valerate
The metabolism of Estradiol valerate can be decreased when combined with Irbesartan.
Estrone
The metabolism of Estrone can be decreased when combined with Irbesartan.
Eszopiclone
The metabolism of Eszopiclone can be decreased when combined with Irbesartan.
Etanercept
The risk or severity of adverse effects can be increased when Irbesartan is combined with Etanercept.
Ethacrynate
The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Irbesartan.
Ethacrynic Acid
The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Irbesartan.
Etodolac
The metabolism of Etodolac can be decreased when combined with Irbesartan.
Etofenamate
The risk or severity of adverse effects can be increased when Irbesartan is combined with Etofenamate.
Etoricoxib
The metabolism of Etoricoxib can be decreased when combined with Irbesartan.
Etravirine
The metabolism of Etravirine can be decreased when combined with Irbesartan.
Evening primrose oil
The risk or severity of adverse effects can be increased when Irbesartan is combined with Evening primrose oil.
Felbinac
The risk or severity of adverse effects can be increased when Irbesartan is combined with Felbinac.
Felodipine
The metabolism of Irbesartan can be decreased when combined with Felodipine.
Fenbufen
The risk or severity of adverse effects can be increased when Irbesartan is combined with Fenbufen.
Fenoldopam
Fenoldopam may increase the hypotensive activities of Irbesartan.
Fenoprofen
The risk or severity of adverse effects can be increased when Irbesartan is combined with Fenoprofen.
Ferulic Acid
Irbesartan may increase the hypotensive activities of Ferulic acid.
Fesoterodine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Irbesartan.
Floctafenine
The risk or severity of adverse effects can be increased when Irbesartan is combined with Floctafenine.
Floxuridine
The metabolism of Irbesartan can be decreased when combined with Floxuridine.
Fluconazole
The metabolism of Irbesartan can be decreased when combined with Fluconazole.
Flunarizine
The metabolism of Flunarizine can be decreased when combined with Irbesartan.
Flunitrazepam
The metabolism of Flunitrazepam can be decreased when combined with Irbesartan.
Fluorouracil
The metabolism of Irbesartan can be decreased when combined with Fluorouracil.
Fluoxetine
The metabolism of Fluoxetine can be decreased when combined with Irbesartan.
Flurbiprofen
The metabolism of Flurbiprofen can be decreased when combined with Irbesartan.
Fluvastatin
The serum concentration of Fluvastatin can be increased when it is combined with Irbesartan.
Fluvoxamine
The metabolism of Irbesartan can be decreased when combined with Fluvoxamine.
Formoterol
The metabolism of Formoterol can be decreased when combined with Irbesartan.
Fosinopril
The risk or severity of adverse effects can be increased when Irbesartan is combined with Fosinopril.
Fosphenytoin
The metabolism of Irbesartan can be increased when combined with Fosphenytoin.
Fostamatinib
Fostamatinib may increase the antihypertensive activities of Irbesartan.
Furazolidone
Furazolidone may increase the hypotensive activities of Irbesartan.
Furosemide
The risk or severity of adverse effects can be increased when Furosemide is combined with Irbesartan.
Gemfibrozil
The metabolism of Irbesartan can be decreased when combined with Gemfibrozil.
Gliclazide
The metabolism of Gliclazide can be decreased when combined with Irbesartan.
Glimepiride
The metabolism of Glimepiride can be decreased when combined with Irbesartan.
Glipizide
The metabolism of Glipizide can be decreased when combined with Irbesartan.
Glyburide
The metabolism of Glyburide can be decreased when combined with Irbesartan.
Guanabenz
Guanabenz may increase the hypotensive activities of Irbesartan.
Guanadrel
Guanadrel may increase the hypotensive activities of Irbesartan.
Guanethidine
Irbesartan may increase the hypotensive activities of Guanethidine.
Guanfacine
The metabolism of Guanfacine can be decreased when combined with Irbesartan.
Halofantrine
The metabolism of Halofantrine can be decreased when combined with Irbesartan.
Haloperidol
The metabolism of Haloperidol can be decreased when combined with Irbesartan.
Halothane
The metabolism of Halothane can be decreased when combined with Irbesartan.
Heparin
Heparin may increase the hyperkalemic activities of Irbesartan.
Hexobarbital
The metabolism of Hexobarbital can be decreased when combined with Irbesartan.
Histamine
The metabolism of Histamine can be decreased when combined with Irbesartan.
Hydralazine
Hydralazine may increase the hypotensive activities of Irbesartan.
Hydrochlorothiazide
Hydrochlorothiazide may increase the hypotensive activities of Irbesartan.
Hydroflumethiazide
Hydroflumethiazide may increase the hypotensive activities of Irbesartan.
Hydromorphone
The metabolism of Hydromorphone can be decreased when combined with Irbesartan.
Ibrutinib
The serum concentration of Ibrutinib can be increased when it is combined with Irbesartan.
Ibuprofen
The metabolism of Ibuprofen can be decreased when combined with Irbesartan.
Icatibant
The risk or severity of adverse effects can be increased when Irbesartan is combined with Icatibant.
Idarubicin
The metabolism of Idarubicin can be decreased when combined with Irbesartan.
Ifosfamide
The metabolism of Ifosfamide can be decreased when combined with Irbesartan.
Iloprost
The risk or severity of adverse effects can be increased when Iloprost is combined with Irbesartan.
Imatinib
The metabolism of Imatinib can be decreased when combined with Irbesartan.
Imidapril
The risk or severity of adverse effects can be increased when Irbesartan is combined with Imidapril.
Imipramine
The risk or severity of adverse effects can be increased when Imipramine is combined with Irbesartan.
Indapamide
Indapamide may increase the hypotensive activities of Irbesartan.
Indinavir
The metabolism of Irbesartan can be decreased when combined with Indinavir.
INDINAVIR ANHYDROUS
The metabolism of Irbesartan can be decreased when combined with Indinavir.
Indobufen
The risk or severity of adverse effects can be increased when Irbesartan is combined with Indobufen.
Indomethacin
The metabolism of Indomethacin can be decreased when combined with Irbesartan.
Indoramin
Indoramin may increase the hypotensive activities of Irbesartan.
Iproniazid
Iproniazid may increase the hypotensive activities of Irbesartan.
Isocarboxazid
Isocarboxazid may increase the hypotensive activities of Irbesartan.
Isoflurane
The risk or severity of adverse effects can be increased when Isoflurane is combined with Irbesartan.
Isosorbide Dinitrate
The risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Irbesartan.
Isosorbide Mononitrate
The risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Irbesartan.
Isoxsuprine
The risk or severity of adverse effects can be increased when Irbesartan is combined with Isoxsuprine.
Isradipine
Isradipine may increase the hypotensive activities of Irbesartan.
Ixazomib
The metabolism of Ixazomib can be decreased when combined with Irbesartan.
Kebuzone
The risk or severity of adverse effects can be increased when Irbesartan is combined with Kebuzone.
Ketamine
The metabolism of Ketamine can be decreased when combined with Irbesartan.
Ketanserin
Ketanserin may increase the hypotensive activities of Irbesartan.
Ketoconazole
The metabolism of Irbesartan can be decreased when combined with Ketoconazole.
Ketoprofen
The metabolism of Ketoprofen can be decreased when combined with Irbesartan.
Ketorolac
The risk or severity of adverse effects can be increased when Irbesartan is combined with Ketorolac.
Labetalol
Labetalol may increase the hypotensive activities of Irbesartan.
Lacidipine
Irbesartan may increase the hypotensive activities of Lacidipine.
Lansoprazole
The metabolism of Lansoprazole can be decreased when combined with Irbesartan.
Lapatinib
The metabolism of Irbesartan can be decreased when combined with Lapatinib.
Latanoprost
Latanoprost may increase the hypotensive activities of Irbesartan.
Leflunomide
The metabolism of Leflunomide can be decreased when combined with Irbesartan.
Lercanidipine
Lercanidipine may increase the hypotensive activities of Irbesartan.
Lesinurad
The metabolism of Lesinurad can be decreased when combined with Irbesartan.
Levobunolol
The risk or severity of adverse effects can be increased when Irbesartan is combined with Levobunolol.
Levobupivacaine
The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Irbesartan.
Levodopa
Irbesartan may increase the orthostatic hypotensive activities of Levodopa.
Levomilnacipran
The metabolism of Levomilnacipran can be decreased when combined with Irbesartan.
Levosimendan
The risk or severity of adverse effects can be increased when Levosimendan is combined with Irbesartan.
Lidocaine
The metabolism of Lidocaine can be decreased when combined with Irbesartan.
Limonene, (+)-
The risk or severity of adverse effects can be increased when Irbesartan is combined with (4R)-limonene.
Lisinopril
The risk or severity of adverse effects can be increased when Irbesartan is combined with Lisinopril.
Lisinopril Anhydrous
The risk or severity of adverse effects can be increased when Irbesartan is combined with Lisinopril.
Lisuride
The risk or severity of adverse effects can be increased when Lisuride is combined with Irbesartan.
Lithium
The serum concentration of Lithium can be increased when it is combined with Irbesartan.
Lithium Cation
The serum concentration of Lithium can be increased when it is combined with Irbesartan.
Lofexidine
Irbesartan may increase the hypotensive activities of Lofexidine.
Loperamide
The metabolism of Loperamide can be decreased when combined with Irbesartan.
Loratadine
The metabolism of Loratadine can be decreased when combined with Irbesartan.
Lornoxicam
The metabolism of Lornoxicam can be decreased when combined with Irbesartan.
Losartan
The metabolism of Irbesartan can be decreased when combined with Losartan.
Lovastatin
The serum concentration of Lovastatin can be increased when it is combined with Irbesartan.
Loxoprofen
The risk or severity of adverse effects can be increased when Irbesartan is combined with Loxoprofen.
Lumacaftor
The serum concentration of Irbesartan can be increased when it is combined with Lumacaftor.
Macitentan
Irbesartan may increase the hypotensive activities of Macitentan.
Magnesium Salicylate
The risk or severity of adverse effects can be increased when Irbesartan is combined with Magnesium salicylate.
Manidipine
Irbesartan may increase the hypotensive activities of Manidipine.
Mannitol
The risk or severity of adverse effects can be increased when Mannitol is combined with Irbesartan.
Masoprocol
The risk or severity of adverse effects can be increased when Irbesartan is combined with Masoprocol.
Mecamylamine
Mecamylamine may increase the hypotensive activities of Irbesartan.
Meclofenamate
The risk or severity of adverse effects can be increased when Irbesartan is combined with Meclofenamic acid.
Meclofenamic Acid
The risk or severity of adverse effects can be increased when Irbesartan is combined with Meclofenamic acid.
Mefenamic Acid
The metabolism of Mefenamic acid can be decreased when combined with Irbesartan.
Melatonin
The metabolism of Melatonin can be decreased when combined with Irbesartan.
Meloxicam
The metabolism of Meloxicam can be decreased when combined with Irbesartan.
Mephenytoin
The metabolism of Mephenytoin can be decreased when combined with Irbesartan.
Mephobarbital
Methylphenobarbital may increase the hypotensive activities of Irbesartan.
Mepirodipine
Irbesartan may increase the antihypertensive activities of Barnidipine.
Mesalamine
The risk or severity of adverse effects can be increased when Irbesartan is combined with Mesalazine.
Mestranol
The metabolism of Mestranol can be decreased when combined with Irbesartan.
Metergoline
The risk or severity of adverse effects can be increased when Metergoline is combined with Irbesartan.
Methadone
The metabolism of Methadone can be decreased when combined with Irbesartan.
Methazolamide
The risk or severity of adverse effects can be increased when Methazolamide is combined with Irbesartan.
Methohexital
Methohexital may increase the hypotensive activities of Irbesartan.
Methoxyflurane
The metabolism of Methoxyflurane can be decreased when combined with Irbesartan.
Methyclothiazide
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Irbesartan.
Methyldopa
Methyldopa may increase the hypotensive activities of Irbesartan.
METHYLDOPA ANHYDROUS
Methyldopa may increase the hypotensive activities of Irbesartan.
Methylene blue
Methylene blue may increase the hypotensive activities of Irbesartan.
Methylergonovine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Irbesartan.
Methylphenidate
Methylphenidate may decrease the antihypertensive activities of Irbesartan.
Methysergide
The risk or severity of adverse effects can be increased when Methysergide is combined with Irbesartan.
Metipranolol
Irbesartan may increase the hypotensive activities of Metipranolol.
Metolazone
Metolazone may increase the hypotensive activities of Irbesartan.
Metoprolol
The serum concentration of Metoprolol can be increased when it is combined with Irbesartan.
Metronidazole
The metabolism of Metronidazole can be decreased when combined with Irbesartan.
Metyrosine
Irbesartan may increase the hypotensive activities of Metyrosine.
Mibefradil
Irbesartan may increase the hypotensive activities of Mibefradil.
Midostaurin
The metabolism of Irbesartan can be decreased when combined with Midostaurin.
Mifepristone
The serum concentration of Irbesartan can be increased when it is combined with Mifepristone.
Minaprine
Minaprine may increase the hypotensive activities of Irbesartan.
Minoxidil
Minoxidil may increase the hypotensive activities of Irbesartan.
Mirtazapine
The metabolism of Mirtazapine can be decreased when combined with Irbesartan.
Moclobemide
The metabolism of Moclobemide can be decreased when combined with Irbesartan.
Moexipril
The risk or severity of adverse effects can be increased when Irbesartan is combined with Moexipril.
Molsidomine
Molsidomine may increase the hypotensive activities of Irbesartan.
Montelukast
The metabolism of Montelukast can be decreased when combined with Irbesartan.
Morphine
The metabolism of Morphine can be decreased when combined with Irbesartan.
Moxonidine
Moxonidine may increase the hypotensive activities of Irbesartan.
MYCOPHENOLATE
The risk or severity of adverse effects can be increased when Irbesartan is combined with Mycophenolic acid.
Mycophenolate Mofetil
The metabolism of Mycophenolate mofetil can be decreased when combined with Irbesartan.
Mycophenolic Acid
The risk or severity of adverse effects can be increased when Irbesartan is combined with Mycophenolic acid.
Nabilone
The risk or severity of adverse effects can be increased when Nabilone is combined with Irbesartan.
Nabumetone
The risk or severity of adverse effects can be increased when Irbesartan is combined with Nabumetone.
Nadolol
Irbesartan may increase the hypotensive activities of Nadolol.
Nadroparin
Nadroparin may increase the hyperkalemic activities of Irbesartan.
Naftifine
The risk or severity of adverse effects can be increased when Irbesartan is combined with Naftifine.
Naloxone
The metabolism of Naloxone can be decreased when combined with Irbesartan.
Naproxen
The metabolism of Naproxen can be decreased when combined with Irbesartan.
Nateglinide
The metabolism of Nateglinide can be decreased when combined with Irbesartan.
Nebivolol
Irbesartan may increase the hypotensive activities of Nebivolol.
Nepafenac
The risk or severity of adverse effects can be increased when Irbesartan is combined with Nepafenac.
Nesiritide
The risk or severity of adverse effects can be increased when Irbesartan is combined with Nesiritide.
Netupitant
The metabolism of Netupitant can be decreased when combined with Irbesartan.
Nevirapine
The metabolism of Nevirapine can be decreased when combined with Irbesartan.
Nialamide
Nialamide may increase the hypotensive activities of Irbesartan.
Nicardipine
The metabolism of Irbesartan can be decreased when combined with Nicardipine.
Nicergoline
The risk or severity of adverse effects can be increased when Nicergoline is combined with Irbesartan.
Niclosamide
The metabolism of Niclosamide can be decreased when combined with Irbesartan.
Nicorandil
Nicorandil may increase the hyperkalemic activities of Irbesartan.
Nicotine
The metabolism of Nicotine can be decreased when combined with Irbesartan.
Nicotine Polacrilex
The metabolism of Nicotine can be decreased when combined with Irbesartan.
Nifedipine
The risk or severity of adverse effects can be increased when Irbesartan is combined with Nifedipine.
Niflumic Acid
The risk or severity of adverse effects can be increased when Irbesartan is combined with Niflumic Acid.
Nilotinib
The metabolism of Irbesartan can be decreased when combined with Nilotinib.
Nilvadipine
Irbesartan may increase the hypotensive activities of Nilvadipine.
Nimesulide
The risk or severity of adverse effects can be increased when Irbesartan is combined with Nimesulide.
Nimodipine
Nimodipine may increase the hypotensive activities of Irbesartan.
Nisoldipine
Nisoldipine may increase the hypotensive activities of Irbesartan.
Nitrendipine
Irbesartan may increase the hypotensive activities of Nitrendipine.
Nitric Oxide
The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Irbesartan.
Nitroglycerin
The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Irbesartan.
Nitroprusside
Nitroprusside may increase the hypotensive activities of Irbesartan.
Nortriptyline
The metabolism of Nortriptyline can be decreased when combined with Irbesartan.
Obinutuzumab
Irbesartan may increase the hypotensive activities of Obinutuzumab.
Oenothera biennis seed extract
The risk or severity of adverse effects can be increased when Irbesartan is combined with Evening primrose oil.
Olmesartan
Olmesartan may increase the hypotensive activities of Irbesartan.
Olodaterol
The metabolism of Olodaterol can be decreased when combined with Irbesartan.
Olopatadine
The risk or severity of adverse effects can be increased when Irbesartan is combined with Olopatadine.
Olsalazine
The risk or severity of adverse effects can be increased when Irbesartan is combined with Olsalazine.
Ombitasvir
The metabolism of Ombitasvir can be decreased when combined with Irbesartan.
Omeprazole
The metabolism of Omeprazole can be decreased when combined with Irbesartan.
Ondansetron
The metabolism of Ondansetron can be decreased when combined with Irbesartan.
Ospemifene
The metabolism of Ospemifene can be decreased when combined with Irbesartan.
Oxaprozin
The metabolism of Oxaprozin can be decreased when combined with Irbesartan.
Oxprenolol
Irbesartan may increase the hypotensive activities of Oxprenolol.
Oxyphenbutazone
The risk or severity of adverse effects can be increased when Irbesartan is combined with Oxyphenbutazone.
Paclitaxel
The metabolism of Paclitaxel can be decreased when combined with Irbesartan.
Palmidrol
The risk or severity of adverse effects can be increased when Irbesartan is combined with Palmidrol.
Papaverine
The risk or severity of adverse effects can be increased when Irbesartan is combined with Papaverine.
Paramethadione
The metabolism of Paramethadione can be decreased when combined with Irbesartan.
Parecoxib
The metabolism of Parecoxib can be decreased when combined with Irbesartan.
Paregoric
The metabolism of Morphine can be decreased when combined with Irbesartan.
Pargyline
Pargyline may increase the hypotensive activities of Irbesartan.
Parnaparin
Parnaparin may increase the hyperkalemic activities of Irbesartan.
Parthenolide
The risk or severity of adverse effects can be increased when Irbesartan is combined with Parthenolide.
Pazopanib
The metabolism of Pazopanib can be decreased when combined with Irbesartan.
Penbutolol
Irbesartan may increase the hypotensive activities of Penbutolol.
Pentamidine
The metabolism of Pentamidine can be decreased when combined with Irbesartan.
Pentobarbital
Pentobarbital may increase the hypotensive activities of Irbesartan.
Pentoxifylline
Pentoxifylline may increase the hypotensive activities of Irbesartan.
Pergolide
The risk or severity of adverse effects can be increased when Pergolide is combined with Irbesartan.
Perindopril
The risk or severity of adverse effects can be increased when Irbesartan is combined with Perindopril.
Perphenazine
The metabolism of Perphenazine can be decreased when combined with Irbesartan.
Phenacetin
The metabolism of Phenacetin can be decreased when combined with Irbesartan.
Phenelzine
Phenelzine may increase the hypotensive activities of Irbesartan.
Phenobarbital
The metabolism of Irbesartan can be increased when combined with Phenobarbital.
Phenoxybenzamine
Phenoxybenzamine may increase the hypotensive activities of Irbesartan.
Phenprocoumon
The metabolism of Phenprocoumon can be decreased when combined with Irbesartan.
Phentolamine
Phentolamine may increase the hypotensive activities of Irbesartan.
Phentolamine Mesylate
Phentolamine may increase the hypotensive activities of Irbesartan.
Phenylbutazone
The metabolism of Phenylbutazone can be decreased when combined with Irbesartan.
Phenytoin
The metabolism of Irbesartan can be increased when combined with Phenytoin.
Pimecrolimus
The risk or severity of adverse effects can be increased when Irbesartan is combined with Pimecrolimus.
Pinacidil
Pinacidil may increase the hypotensive activities of Irbesartan.
Pindolol
Pindolol may increase the hypotensive activities of Irbesartan.
Pioglitazone
The metabolism of Pioglitazone can be decreased when combined with Irbesartan.
Pipamperone
The risk or severity of adverse effects can be increased when Pipamperone is combined with Irbesartan.
Pirfenidone
The risk or severity of adverse effects can be increased when Irbesartan is combined with Pirfenidone.
Piroxicam
The metabolism of Piroxicam can be decreased when combined with Irbesartan.
Piroxicam-Beta-Cyclodextrin
The metabolism of Piroxicam can be decreased when combined with Irbesartan.
Pitavastatin
The serum concentration of Pitavastatin can be increased when it is combined with Irbesartan.
Polythiazide
Irbesartan may increase the hypotensive activities of Polythiazide.
Ponatinib
The metabolism of Ponatinib can be decreased when combined with Irbesartan.
Pramipexole
The risk or severity of adverse effects can be increased when Pramipexole is combined with Irbesartan.
Prasugrel
The metabolism of Prasugrel can be decreased when combined with Irbesartan.
Pravastatin
The serum concentration of Pravastatin can be increased when it is combined with Irbesartan.
Prazosin
Prazosin may increase the hypotensive activities of Irbesartan.
Primidone
The metabolism of Irbesartan can be increased when combined with Primidone.
Procaine
Procaine may increase the hypotensive activities of Irbesartan.
Procarbazine
Procarbazine may increase the hypotensive activities of Irbesartan.
Progesterone
The metabolism of Progesterone can be decreased when combined with Irbesartan.
Proguanil
The metabolism of Proguanil can be decreased when combined with Irbesartan.
Promazine
The metabolism of Promazine can be decreased when combined with Irbesartan.
Propofol
The metabolism of Propofol can be decreased when combined with Irbesartan.
Propranolol
Propranolol may increase the hypotensive activities of Irbesartan.
Pyrimethamine
The metabolism of Irbesartan can be decreased when combined with Pyrimethamine.
Quazepam
The metabolism of Quazepam can be decreased when combined with Irbesartan.
Quetiapine
The risk or severity of adverse effects can be increased when Irbesartan is combined with Quetiapine.
Quetiapine fumarate
The risk or severity of adverse effects can be increased when Irbesartan is combined with Quetiapine.
Quinapril
The risk or severity of adverse effects can be increased when Irbesartan is combined with Quinapril.
Quinidine
The metabolism of Quinidine can be decreased when combined with Irbesartan.
Quinine
The metabolism of Quinine can be decreased when combined with Irbesartan.
Rabeprazole
The metabolism of Irbesartan can be decreased when combined with Rabeprazole.
Ramipril
The risk or severity of adverse effects can be increased when Irbesartan is combined with Ramipril.
Rasagiline
Rasagiline may increase the hypotensive activities of Irbesartan.
Remifentanil
The risk or severity of adverse effects can be increased when Remifentanil is combined with Irbesartan.
Repaglinide
The metabolism of Repaglinide can be decreased when combined with Irbesartan.
Rescinnamine
The risk or severity of adverse effects can be increased when Irbesartan is combined with Rescinnamine.
Reserpine
Reserpine may increase the hypotensive activities of Irbesartan.
Resveratrol
The risk or severity of adverse effects can be increased when Irbesartan is combined with Resveratrol.
Reviparin
Reviparin may increase the hyperkalemic activities of Irbesartan.
Reviparin sodium
Reviparin may increase the hyperkalemic activities of Irbesartan.
Rifampin
The metabolism of Irbesartan can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Irbesartan can be increased when combined with Rifapentine.
Rilmenidine
Rilmenidine may increase the hypotensive activities of Irbesartan.
Rilpivirine
The serum concentration of Rilpivirine can be increased when it is combined with Irbesartan.
Riociguat
The metabolism of Riociguat can be decreased when combined with Irbesartan.
Risperidone
Irbesartan may increase the hypotensive activities of Risperidone.
Rituximab
Irbesartan may increase the hypotensive activities of Rituximab.
Rofecoxib
The metabolism of Rofecoxib can be decreased when combined with Irbesartan.
Ropinirole
The risk or severity of adverse effects can be increased when Ropinirole is combined with Irbesartan.
Ropivacaine
The risk or severity of adverse effects can be increased when Ropivacaine is combined with Irbesartan.
Rosiglitazone
The metabolism of Rosiglitazone can be decreased when combined with Irbesartan.
Rosuvastatin
The serum concentration of Rosuvastatin can be increased when it is combined with Irbesartan.
Rotigotine
The risk or severity of adverse effects can be increased when Rotigotine is combined with Irbesartan.
Rucaparib
The metabolism of Irbesartan can be decreased when combined with Rucaparib.
Sacubitril
The risk or severity of adverse effects can be increased when Sacubitril is combined with Irbesartan.
Salicylamide
The risk or severity of adverse effects can be increased when Irbesartan is combined with Salicylamide.
Salicylic Acid
The metabolism of Salicylic acid can be decreased when combined with Irbesartan.
Salsalate
The risk or severity of adverse effects can be increased when Irbesartan is combined with Salsalate.
Secobarbital
The metabolism of Irbesartan can be increased when combined with Secobarbital.
Selegiline
The metabolism of Selegiline can be decreased when combined with Irbesartan.
Selexipag
The metabolism of Selexipag can be decreased when combined with Irbesartan.
Serratiopeptidase
The risk or severity of adverse effects can be increased when Irbesartan is combined with Serrapeptase.
Sertraline
The metabolism of Sertraline can be decreased when combined with Irbesartan.
Sevoflurane
The risk or severity of adverse effects can be increased when Sevoflurane is combined with Irbesartan.
Sildenafil
Sildenafil may increase the antihypertensive activities of Irbesartan.
Simvastatin
The serum concentration of Simvastatin can be increased when it is combined with Irbesartan.
Sitagliptin
The metabolism of Sitagliptin can be decreased when combined with Irbesartan.
Sitagliptin Phosphate
The metabolism of Sitagliptin can be decreased when combined with Irbesartan.
Sodium Phosphate
Irbesartan may increase the nephrotoxic activities of Sodium phosphate.
Sodium Phosphate, Monobasic
Irbesartan may increase the nephrotoxic activities of Sodium phosphate.
SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
Irbesartan may increase the nephrotoxic activities of Sodium phosphate.
Sorafenib
The metabolism of Irbesartan can be decreased when combined with Sorafenib.
Sotalol
The risk or severity of adverse effects can be increased when Sotalol is combined with Irbesartan.
Spirapril
The risk or severity of adverse effects can be increased when Irbesartan is combined with Spirapril.
Spironolactone
The risk or severity of adverse effects can be increased when Spironolactone is combined with Irbesartan.
Streptokinase
The risk or severity of adverse effects can be increased when Streptokinase is combined with Irbesartan.
Sufentanil
The risk or severity of adverse effects can be increased when Sufentanil is combined with Irbesartan.
Sulfadiazine
The metabolism of Irbesartan can be decreased when combined with Sulfadiazine.
Sulfamethoxazole
The metabolism of Irbesartan can be decreased when combined with Sulfamethoxazole.
Sulfamoxole
The metabolism of Sulfamoxole can be decreased when combined with Irbesartan.
Sulfasalazine
The risk or severity of adverse effects can be increased when Irbesartan is combined with Sulfasalazine.
Sulfinpyrazone
The metabolism of Sulfinpyrazone can be decreased when combined with Irbesartan.
Sulfisoxazole
The metabolism of Irbesartan can be decreased when combined with Sulfisoxazole.
Sulindac
The risk or severity of adverse effects can be increased when Irbesartan is combined with Sulindac.
Suprofen
The metabolism of Suprofen can be decreased when combined with Irbesartan.
Tadalafil
Tadalafil may increase the antihypertensive activities of Irbesartan.
Talinolol
Irbesartan may increase the hypotensive activities of Talinolol.
Tamoxifen
The metabolism of Tamoxifen can be decreased when combined with Irbesartan.
Tamsulosin
The risk or severity of adverse effects can be increased when Tamsulosin is combined with Irbesartan.
Tapentadol
The metabolism of Tapentadol can be decreased when combined with Irbesartan.
Tazarotene
The metabolism of Tazarotene can be decreased when combined with Irbesartan.
Telmisartan
Telmisartan may increase the hypotensive activities of Irbesartan.
Temazepam
The metabolism of Temazepam can be decreased when combined with Irbesartan.
Tenoxicam
The metabolism of Tenoxicam can be decreased when combined with Irbesartan.
Terazosin
The risk or severity of adverse effects can be increased when Irbesartan is combined with Terazosin.
Terbinafine
The metabolism of Terbinafine can be decreased when combined with Irbesartan.
Terfenadine
The metabolism of Terfenadine can be decreased when combined with Irbesartan.
Teriflunomide
The metabolism of Irbesartan can be decreased when combined with Teriflunomide.
Terlipressin
Irbesartan may increase the hypotensive activities of Terlipressin.
Testosterone
The metabolism of Testosterone can be decreased when combined with Irbesartan.
Testosterone Cypionate
The metabolism of Testosterone cypionate can be decreased when combined with Irbesartan.
Testosterone Enanthate
The metabolism of Testosterone enanthate can be decreased when combined with Irbesartan.
Testosterone Undecanoate
The metabolism of Testosterone undecanoate can be decreased when combined with Irbesartan.
Tetrahydrocannabinol
The serum concentration of Dronabinol can be increased when it is combined with Irbesartan.
Thalidomide
The metabolism of Thalidomide can be decreased when combined with Irbesartan.
Theodrenaline
Irbesartan may increase the hypotensive activities of Theodrenaline.
Theophylline
The metabolism of Theophylline can be decreased when combined with Irbesartan.
Theophylline anhydrous
The metabolism of Theophylline can be decreased when combined with Irbesartan.
Thiamylal
The metabolism of Thiamylal can be decreased when combined with Irbesartan.
Thiopental
Thiopental may increase the hypotensive activities of Irbesartan.
Thiopental Sodium
Thiopental may increase the hypotensive activities of Irbesartan.
Thioridazine
The serum concentration of Thioridazine can be increased when it is combined with Irbesartan.
Tiaprofenic Acid
The risk or severity of adverse effects can be increased when Irbesartan is combined with Tiaprofenic acid.
Tibolone
Irbesartan may increase the hypotensive activities of Tibolone.
Ticagrelor
The metabolism of Irbesartan can be decreased when combined with Ticagrelor.
Ticlopidine
The metabolism of Irbesartan can be decreased when combined with Ticlopidine.
Timolol
Timolol may increase the hypotensive activities of Irbesartan.
Timolol Anhydrous
Timolol may increase the hypotensive activities of Irbesartan.
Tinzaparin
Tinzaparin may increase the hyperkalemic activities of Irbesartan.
Tinzaparin sodium
Tinzaparin may increase the hyperkalemic activities of Irbesartan.
Tizanidine
The risk or severity of adverse effects can be increased when Tizanidine is combined with Irbesartan.
Tolazoline
Tolazoline may increase the hypotensive activities of Irbesartan.
Tolbutamide
The metabolism of Irbesartan can be decreased when combined with Tolbutamide.
Tolcapone
The risk or severity of adverse effects can be increased when Tolcapone is combined with Irbesartan.
Tolfenamic Acid
The risk or severity of adverse effects can be increased when Irbesartan is combined with Tolfenamic Acid.
Tolmetin
The risk or severity of adverse effects can be increased when Irbesartan is combined with Tolmetin.
Toloxatone
Toloxatone may increase the hypotensive activities of Irbesartan.
Tolterodine
The metabolism of Tolterodine can be decreased when combined with Irbesartan.
Tolvaptan
The serum concentration of Tolvaptan can be increased when it is combined with Irbesartan.
Torsemide
The metabolism of Torasemide can be decreased when combined with Irbesartan.
Trabectedin
The metabolism of Trabectedin can be decreased when combined with Irbesartan.
Trandolapril
The risk or severity of adverse effects can be increased when Irbesartan is combined with Trandolapril.
Tranilast
The risk or severity of adverse effects can be increased when Irbesartan is combined with Tranilast.
Tranylcypromine
Tranylcypromine may increase the hypotensive activities of Irbesartan.
Travoprost
Travoprost may increase the hypotensive activities of Irbesartan.
Treprostinil
The metabolism of Treprostinil can be decreased when combined with Irbesartan.
Tretinoin
The metabolism of Tretinoin can be decreased when combined with Irbesartan.
Triamterene
Irbesartan may increase the hyperkalemic activities of Triamterene.
Tribenoside
The risk or severity of adverse effects can be increased when Irbesartan is combined with Tribenoside.
Trichlormethiazide
Trichlormethiazide may increase the hypotensive activities of Irbesartan.
Trimethadione
The metabolism of Trimethadione can be decreased when combined with Irbesartan.
Trimethaphan
Trimethaphan may increase the hypotensive activities of Irbesartan.
Trimethoprim
Trimethoprim may increase the hyperkalemic activities of Irbesartan.
Trimipramine
The metabolism of Trimipramine can be decreased when combined with Irbesartan.
Troglitazone
The metabolism of Troglitazone can be decreased when combined with Irbesartan.
UNOPROSTONE
Irbesartan may increase the hypotensive activities of Unoprostone.
Urapidil
Urapidil may increase the hypotensive activities of Irbesartan.
Valdecoxib
The metabolism of Valdecoxib can be decreased when combined with Irbesartan.
Valproate
The metabolism of Valproic Acid can be decreased when combined with Irbesartan.
Valproic Acid
The metabolism of Valproic Acid can be decreased when combined with Irbesartan.
Valsartan
The metabolism of Valsartan can be decreased when combined with Irbesartan.
Vardenafil
Vardenafil may increase the antihypertensive activities of Irbesartan.
Velpatasvir
The metabolism of Velpatasvir can be decreased when combined with Irbesartan.
Vemurafenib
The serum concentration of Irbesartan can be increased when it is combined with Vemurafenib.
Venlafaxine
The metabolism of Venlafaxine can be decreased when combined with Irbesartan.
Verapamil
The metabolism of Verapamil can be decreased when combined with Irbesartan.
Vincamine
Irbesartan may increase the hypotensive activities of Vincamine.
Vinpocetine
Irbesartan may increase the hypotensive activities of Vinpocetine.
Vismodegib
The metabolism of Vismodegib can be decreased when combined with Irbesartan.
Voriconazole
The metabolism of Irbesartan can be decreased when combined with Voriconazole.
Vortioxetine
The metabolism of Vortioxetine can be decreased when combined with Irbesartan.
Voxilaprevir
The metabolism of Voxilaprevir can be decreased when combined with Irbesartan.
Warfarin
The metabolism of Warfarin can be decreased when combined with Irbesartan.
Xylometazoline
Irbesartan may increase the hypotensive activities of Xylometazoline.
Yohimbine
Yohimbine may decrease the antihypertensive activities of Irbesartan.
Zafirlukast
The metabolism of Irbesartan can be decreased when combined with Zafirlukast.
Zalcitabine
The metabolism of Zalcitabine can be decreased when combined with Irbesartan.
Zidovudine
The metabolism of Zidovudine can be decreased when combined with Irbesartan.
Zileuton
The metabolism of Zileuton can be decreased when combined with Irbesartan.
Zofenopril
The risk or severity of adverse effects can be increased when Irbesartan is combined with Zofenopril.
Zolpidem
The metabolism of Zolpidem can be decreased when combined with Irbesartan.
Zomepirac
The risk or severity of adverse effects can be increased when Irbesartan is combined with Zomepirac.
Zopiclone
The metabolism of Zopiclone can be decreased when combined with Irbesartan.
